Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (SNSNN, the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed.
The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). Having previously been approved for the Swiss market, Healiva's® acquisition of the complete product dossier should enable the rapid market re-launch of EpiDex®.
The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy that has previously demonstrated clinical efficacy in healing VLUs that are resistant to standard treatments.
We created Healiva® to improve the lives of the millions suffering from chronic wounds by delivering innovative, effective new treatments to patients, said Healiva's® Founder and CEO, Priyanka Dutta-Passecker, PhD, MBA. These remarkable cell therapies will make a pivotal contribution to that mission by addressing crucial needs in early- and late-stage chronic wound care. By adding these pioneering technologies to our growing portfolio of wound treatments, we will be able to continue our rapid growth by progressing to commercialization within four years of founding.
Continue read on benzinga.com